# Pfizer India defends patient safety after Karnataka FDA crackdown

> Pfizer India says patient safety remains top priority after Karnataka FDA cancels 16 drug licenses for counterfeit medicines
- Title: Pfizer India defends patient safety after Karnataka FDA…
- Summary: Pfizer India says patient safety remains top priority after Karnataka FDA cancels 16 drug licenses for counterfeit medicines Pfizer India removed counterfeit…
- Keywords: pfizer india, karnataka fda, counterfeit drugs, patient safety, drug licenses, securities, Pfizer, India, defends, patient, safety, Karnataka
- Source: The Economic Times — https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/pfizer-india-speaks-up-after-karnataka-fda-crackdown-says-patient-safety-is-top-priority/articleshow/134426291.cms
- Author: PTI
- Published: 2026-09-23T05:07:00+00:00
- Read time: 1 min
- Topics: pfizer india, karnataka fda, counterfeit drugs, patient safety, drug licenses, securities
## Pfizer India responds
Pfizer India stated patient safety and product quality are their top priorities after Karnataka FDA canceled 16 drug licenses for counterfeit medicines.

> Patient safety and product quality are of the highest priority for us at Pfizer.
## Karnataka FDA action
Karnataka health regulator canceled 16 drug licenses and suspended eight others for alleged distribution of counterfeit medicines.
## Pfizer's actions
Pfizer removed counterfeit batches from the market and supported efforts to differentiate original from counterfeit products.
## Counterfeit operation
Karnataka FDA busted an unlicensed repacking operation at a farmhouse in Bengaluru South district, seizing Rs 5.05 crore worth of fake drugs.
## Pfizer cooperation
Pfizer has worked with authorities for one month to resolve open queries and protect patient safety.
## Key takeaway

Pfizer India removed counterfeit products and cooperated with authorities following Karnataka FDA's crackdown on fake medicines.